Stockscreener 앱 받기
22.32
4.91%
1.045
전일 마감가:
$21.28
열려 있는:
$21.89
하루 거래량:
53,823
Relative Volume:
0.33
시가총액:
$1.14B
수익:
$32.72M
순이익/손실:
$-27.55M
주가수익비율:
-39.04
EPS:
-0.5718
순현금흐름:
$-41.40M
1주 성능:
-2.51%
1개월 성능:
-36.68%
6개월 성능:
-32.76%
1년 성능:
-19.67%
1일 변동 폭
$21.55
$22.55
1주일 범위
$21.14
$24.50
52주 변동 폭
$14.78
$57.14
나노바이오틱스 Stock (NBTX) Company Profile
Compare NBTX vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NBTX
Nanobiotix Adr
|
22.32 | 1.14B | 32.72M | -27.55M | -41.40M | -0.5718 |
VRTX
Vertex Pharmaceuticals Inc
|
509.10 | 129.04B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
238.23 | 95.11B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
800.96 | 82.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
847.89 | 53.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.80 | 42.06B | 5.76B | 514.49M | 1.10B | 4.4813 |
나노바이오틱스 Stock (NBTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-15 | 재개 | Guggenheim | Buy |
| 2026-02-06 | 개시 | TD Cowen | Buy |
| 2024-08-28 | 개시 | Guggenheim | Buy |
| 2023-12-08 | 개시 | Leerink Partners | Outperform |
| 2021-01-06 | 개시 | Evercore ISI | Outperform |
나노바이오틱스 주식(NBTX)의 최신 뉴스
NBTX Q2 2026 Earnings: Wider-Than-Expected Loss Sends Shares Down 7.71%Earnings Volatility Report - https://www.dars.gov.et/
Head and Neck Squamous Cell Carcinoma (HNSCC)Market Insights, Epidemiology, and Market Forecast2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care - GlobeNewswire Inc.
NBTX Edges Lower: Nanobiotix Holds Near $33 as Traders Eye $31.64 SupportRelative Volume - https://www.siam.in/
NBTX Edges Lower: Nanobiotix Holds Near $33 as Traders Eye $31.64 SupportTriangle Correction - dars.gov.et
NBTX Q4 2025 Earnings: Loss per Share of -0.39 Comes In Below Consensus EstimateAnnual Earnings Summary - www.dars.gov.et
NBTX Q4 2025 Earnings: Loss per Share of -0.39 Comes In Below Consensus EstimatePre-Announcement Alert - www.dars.gov.et
NBTX Q4 2025 Earnings: Loss per Share of -0.39 Comes In Below Consensus EstimateRevenue Miss Report - dars.gov.et
NBTX Q4 2025 Earnings: Loss per Share of -0.39 Comes In Below Consensus EstimateAnnual Financial Report - dars.gov.et
Stevanato Group S.p.A. (STVN) Stock Price & News - Syfe
Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday - Benzinga
NBTX Q4 2025 Earnings: $0.39 Per-ADS Loss Misses Estimate by 170.16%, Yet Shares Gain 5.17%Buyback Announcement Report - dars.gov.et
NBTX Q4 2025 Earnings: $0.39 Per-ADS Loss Misses Estimate by 170.16%, Yet Shares Gain 5.17%Subscription Growth Report - careplusvn.com
NBTX Q4 2025 Earnings: $0.39 Per-ADS Loss Misses Estimate by 170.16%, Yet Shares Gain 5.17%Positive Surprise Momentum - www.dars.gov.et
Biophytis (BPTS) Peer Comparison – Compare with Others - valueresearchonline.com
Nanobiotix (NBTX) Results Breakdown: EPS Comes in Below Forecast in the Reported Period; Closing Move: The Stock Loses 0.30%Earnings Whisper Number - careplusvn.com
Nanobiotix (NBTX) Results Breakdown: EPS Comes in Below Forecast in the Reported Period; Closing Move: The Stock Loses 0.30%Growth Acceleration Report - dars.gov.et
Nanobiotix (NBTX) Results Breakdown: EPS Comes in Below Forecast in the Reported Period; Closing Move: The Stock Loses 0.30%Final Results - www.dars.gov.et
Nanobiotix (NBTX) Results Breakdown: EPS Comes in Below Forecast in the Reported Period; Closing Move: The Stock Loses 0.30%Healthcare Earnings Report - dars.gov.et
Nanobiotix (NBTX) Q4 2025 Filing Snapshot: EPS Does Not Reach the Reported Estimate under the Current Snapshot; Post-Earnings Trading: The Stock Records a 3.23% DecreaseDownward Estimate Revision - dars.gov.et
Nanobiotix (NBTX) Q4 2025 Filing Snapshot: EPS Does Not Reach the Reported Estimate under the Current Snapshot; Post-Earnings Trading: The Stock Records a 3.23% DecreaseFinancial Data - www.dars.gov.et
NBTX Q4 2025 Earnings: Clinical-Stage Burn and a Wide EPS MissROE Trend Analysis - careplusvn.com
NBTX Q4 2025 Earnings: Clinical-Stage Burn and a Wide EPS MissSubscription Growth Report - dars.gov.et
Nanobiotix (NASDAQ:NBTX) Sees Large Volume IncreaseTime to Buy? - MarketBeat
Nanobiotix S.A. (NBTX) investor group reports 9.4% stake and pre-funded warrants - Stock Titan
Nanobiotix (NBTX) Advances 2.63% to $39.74 as Oncology Pipeline Draws InterestForce Index - dars.gov.et
Nanobiotix (NBTX) Advances 2.63% to $39.74 as Oncology Pipeline Draws InterestMedian Line - dars.gov.et
Nanobiotix (NBTX) Advances 2.63% to $39.74 as Oncology Pipeline Draws InterestSwing Trade Setups - www.dars.gov.et
Nanobiotix (NASDAQ:NBTX) Shares Gap UpHere's What Happened - MarketBeat
Nanobiotix (NBTX) Q4 2025 Earnings: Missed EPS Estimate by Wide Margin as Stock SlipsConsensus Beat Rate - careplusvn.com
Nanobiotix S.A.Sponsored ADR (NASDAQ:NBTX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Nanobiotix (NBTX) Q4 2025 Earnings: Missed EPS Estimate by Wide Margin as Stock SlipsMid-Term Outlook - dars.gov.et
Qatar Investment Authority (NBTX) reports 3.53M Nanobiotix ADRs under sole control - Stock Titan
Nanobiotix (NASDAQ:NBTX) Stock Price Down 5.4%What's Next? - MarketBeat
Nanobiotix (NBTX) Faces Selling Pressure: Approaching Key Support After 4% DeclineVWAP Bounce - careplusvn.com
Nanobiotix (NBTX) Faces Selling Pressure: Approaching Key Support After 4% DeclineFRAMA Signal - dars.gov.et
SK hynix Inc. American Depositary Shares (SKHY) Historical Data - Nasdaq
NBTXNanobiotix ADR Dividends - Finviz
5NRA Forecast — Price Target — Prediction for 2027 - TradingView
5NRA Forecast — Price Target — Prediction for 2027 - TradingView
NBTX Stock Price, Quote & Chart - ChartMill
NBTXNanobiotix ADR Options - Finviz
NANOBIOTIX Announces Closing of Global Offering - GlobeNewswire Inc.
NBTX - Finviz
NANOBIOTIX Announces Closing of Global Offering - GlobeNewswire
NANOBIOTIX Announces Closing of Global Offering - Finansavisen
NANOBIOTIX Announces Closing of Global Offering - GlobeNewswire
Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering - GlobeNewswire Inc.
Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris - Yahoo Finance UK
Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris - Barchart.com
Nanobiotix: Trading Halt on Euronext Paris for a Global Securities Offering - ideal-investisseur.fr
나노바이오틱스 (NBTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.17%
자본화:
|
볼륨(24시간):